← All indications
Wasting Syndrome
A condition of involuntary weight loss of greater then 10% of baseline body weight. It is characterized by atrophy of muscles and depletion of lean body mass. Wasting is a sign of MALNUTRITION as a result of inadequate dietary intake, malabsorption, or hypermetabolism.
Subtype terms (1)
More specific conditions that are subtypes of Wasting Syndrome in the MeSH hierarchy.
- HIV Wasting Syndrome
8 drugs (7 approved, 1 experimental)
Drugs by status
Phase 4 trials (1)
Phase 2 trials (1)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (28)
- Merck Serono
- Helsinn
- DSM
- GTx
- Par Pharmaceuticals
- National Cancer Institute (NCI)
- Cairo University
- Canadian Cancer Trials Group
- Johns Hopkins University
- Wake Forest University
- Mayo Clinic
- General Hospital Groeninge
- International Center for Diarrheal Disease Research
- Pharmaceutical Research Associates, Inc. (PRA)
- Chengdu University of Traditional Chinese Medicines
- University of Sao Paulo
- Pacific Cancer Medical Center Inc.
- University of Nice Sophia Antipolis
- Summit Oncology Associates, Inc.
- Western Maryland Health System
- Innovative Medical Research of South Florida, Inc
- MedQualis
- Forum Health
- United Nations
- Ghent University
- People's Liberation Army of China
- Tetra Bio-Pharma
- William Osler Health Service Brampton
Organization Involved with Phase 2 Indications (42)
- Sapphire Therapeutics
- Acacia Pharma Ltd
- Daiichi Sankyo
- Theratechnologies
- Celgene
- Centocor
- AEterna Zentaris
- Novartis
- Endo Pharmaceuticals
- Pinta Biotherapeutics
- PsiOxus Therapeutics Ltd
- Vicus Therapeutics
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Maastricht University
- Baylor University
- University of London
- Harvard University
- University of Washington
- Northwestern University
- Tata Memorial Hospital
- University of Nottingham
- University of Ottawa
- University of South Florida
- University of Bern
- Kantonsspital Aarau
- University of California, Los Angeles
- University of Basel
- OHR Pharmaceutical
- Alder Biopharmaceuticals
- +12 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (28)
- GlaxoSmithKline
- Microbio Co Ltd
- National Center for Research Resources (NCRR)
- University of Pennsylvania
- Cancer Research UK
- Cancer Treatment Centers of America
- Eastern Cooperative Oncology Group
- McGill University
- Norwegian University of Science and Technology
- Osaka University
- University of Edinburgh
- University of Kansas
- University of Kentucky
- University of South Carolina
- University of Alberta
- University of Westminster
- Aalborg University
- Medical University of South Carolina
- All India Institute of Medical Sciences
- University of Freiburg
- National Taiwan University
- Winthrop University
- University of Erlangen-Nuremberg
- The Beatson West of Scotland Cancer Centre
- Entera Health, Inc
- Queen Margaret Hospital, Dunfermline
- Malteser Krankenhaus Seliger Gerhardt
- University of Geneva